Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
I have received consulting fees, lecture fees and clinical research support from Abbott, Centocor, UCB, Elan and Prometheus
Latest from Gut Education
Register for free content
Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of
Gut.
View free sample issue >>
Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.
- Online First : Online First
- Current issue : Current issue | Mobile site
- Archive : Supplements | Topic collections | Gut tutorials | RSS
-
About the journal
: About the journal | Editorial board | Instructions for authors | Unlocked | Thank you to our reviewers | Most read articles |
Events - Submit a paper : Online submission site | Instructions for authors | Unlocked | Track your article
- Subscribe : Subscribe to the journal | Prices | Email alerts
- Help : Contact us | Feedback form | Reprints | Permissions | Advertising
